TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22565161
Drug: Twice-daily delayed-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily delayed-release mesalamine 1.6 g/day
Study: 19838864
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (2 ml lidocaine of 1%)
Study: 18058494
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg at Week 0 and 40 mg every other week from Week 1 to Week 15
Study: 11747061
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training offered independently of medical treatment
Study: 9205767
Drug: ebrotidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebrotidine 400 mg/day
Study: 9205767
Drug: ebrotidine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebrotidine 800 mg/day
Study: 9205767
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg/day
Study: 9205767
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg/day
Study: 7970506
Drug: Taxol 135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol 135 mg/m2
Study: 7970506
Drug: Taxol 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol 175 mg/m2
Study: 3620002
Drug: Initial test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial test administration (Beck and Zung scales)
Study: 30508645
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D levels categorized in four groups: <25.0, 25.0-49.9, 50.0-74.9, and ≥75.0 nmol/L (highest group as reference)
Study: 28287413
Drug: Fructose Supplement
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose Supplement (FS)
Study: 28287413
Drug: Glucose Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose Supplement (GS)
Study: 24483106
Drug: Shenling Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenling Fuzheng Capsule (SFC) or Qingdu Capsule (QC)
Study: 24483106
Drug: SFC or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC or QC combined with highly active antiretroviral agents
Study: 19903376
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of aspirin
Study: 19903376
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of aspirin
Study: 17011743
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of semantic fluency and narrative recall
Study: 15491387
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of enalapril and losartan (Group A)
Study: 11080322
Drug: Thermoluminescent dosimeter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermoluminescent dosimeter (TLD) measurements of radiation dose to the skin and whole body over the lead apron.
Study: 11080322
Drug: Thermoluminescent dosimeter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermoluminescent dosimeter (TLD) measurements of radiation dose to the whole body under the lead apron.
Study: 30062709
Drug: Quercetin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 1,000 mg/day for 12 weeks
Study: 27501900
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ULDCT) (100 kVp ± 20 and 10 mAs)
Study: 27501900
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT) (100 kVp and 60 mAs)
Study: 20578205
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (1.34 g/kg body weight)
Study: 20578205
Drug: Conventional protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protein diet (0.8 g/kg body weight)
Study: 16404866
Drug: ARTRA (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARTRA (500 mg glucosamine hydrochloride + 500 mg chondroitine sulphate) taken 1 tablet 2 times a day for the first month, then 1 tablet a day for the following 5 months, along with diclofenac sodium 50 mg 2 times a day with gradual decrease as pain decreased.
Study: 16404866
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg twice a day for 6 months (control group).
Study: 10470627
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg i.v. followed by continuous infusion of 170 micrograms kg‐1 min‐1 (with additional 0.5 mg/kg if needed)
Study: 10470627
Drug: Sevoflurane 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 5% inhalation
Study: 1989740
Drug: Promethazine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (0.5 mg.kg‐1 IV + 0.5 mg.kg‐1 IM)
Study: 1989740
Drug: Droperidol (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.075 mg.kg‐1 IV + physiological saline, 0.02 ml.kg‐1 IM)
Study: 27923685
Drug: LVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVR with vehicle solution (Group 2)
Study: 27923685
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution without LVR (Group 3)
Study: 9667681
Drug: r‐HuEPO (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO (200 units kg(‐1) day(‐1) plus oral iron supplements 325 mg p.o. t.i.d.)
Study: 9667681
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no r‐HuEPO treatment)
Study: 28283830
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of fluoroquinolone treatment
Study: 28283830
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of fluoroquinolone treatment
Study: 21982411
Drug: Dalcetrapib 900
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 900 mg plus Ezetimibe 10 mg
Study: 11029965
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg Cu‐glycine chelate
Study: 11029965
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg Cu‐glycine chelate
Study: 8851594
Drug: Ceftazidime as
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime as intermittent bolus (IB) 2 g i.v. every 8 h (q8h) for 2 days
Study: 8851594
Drug: Ceftazidime as
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime as continuous infusion (CI) 3 g continuous infusion over 24 h for 2 days
Study: 8851594
Drug: Ceftazidime (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (both regimens) in presence of tobramycin (4 to 7 mg/kg i.v. q24h)
Study: 6703681
Drug: Ceforanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceforanide (1 g every 12 h)
Study: 6703681
Drug: Cephapirin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephapirin (2 g every 4 h)
Study: 30014664
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride tablets
Study: 26968285
Drug: Immediate intramasseteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intramasseteric injection of 2ml of 8mg/2ml dexamethasone
Study: 26968285
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 2ml of sterile saline solution
Study: 25666690
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy plus TrP‐DN (n = 10)
Study: 25666690
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (n = 10)
Study: 23073338
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment with inactivity on fundus fluorescein angiography at month 3
Study: 23073338
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment with qualitative OCT inactivity at month 5
Study: 23073338
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment with qualitative OCT inactivity at month 8
Study: 23073338
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment with leakage on OCT
Study: 23073338
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment with inactivity on fundus fluorescein angiography at months 3 and 5
Study: 20695184
Drug: Preoperative bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative bowel preparation procedure (Group B)
Study: 20695184
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative bowel preparation (Group A)
Study: 11221150
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) and Fluvoxamine (FVX)
Study: 9095122
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) intravenous up to 30 ng/kg/min for 72 hours after surgery
Study: 8229122
Drug: 160 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/d of megestrol acetate
Study: 8229122
Drug: 800 mg/d
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/d of megestrol acetate
Study: 8229122
Drug: 1,600 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,600 mg/d of megestrol acetate
Study: 3782653
Drug: Polyethylene glycol-modified
Normalized name: Polyethylene glycol-modified uricase
DrugBank: PEG-uricase (DB05321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-modified ragweed extract administered via weekly injections
Study: 3782653
Drug: Polyethylene glycol-modified
Normalized name: Polyethylene glycol-modified uricase
DrugBank: PEG-uricase (DB05321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-modified ragweed extract administered via daily injections until adverse reaction, then switched to weekly schedule
Study: 24022270
Drug: Daclizumab high-yield
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab high-yield process (DAC HYP) 150 mg or 300 mg, administered subcutaneously every four weeks for 52 weeks
Study: 24022270
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered subcutaneously every four weeks for 52 weeks
Study: 21383045
Drug: MK-3207 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3207 200 mg
Study: 21383045
Drug: MK-3207 100
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3207 100 mg
Study: 21383045
Drug: MK-3207 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3207 10 mg
Study: 11082723
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with concomitant chemotherapy (arm B)
Study: 30220407
Drug: PAXG (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAXG (cisplatin 30 mg/m2, nab-paclitaxel 150 mg/m2, gemcitabine 800 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 on days 1-28 every 4 weeks)
Study: 30220407
Drug: nab-paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Study: 27681755
Drug: Both dose
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dose levels of SIB-VMAT
Study: 11494543
Drug: Prolonged IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged IFN therapy
Study: 11494543
Drug: IFN-beta therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta therapy twice a day
Study: 11494543
Drug: IFN-beta therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta therapy daily for 24 weeks
Study: 11494543
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of IFN-alpha and IFN-beta
Study: 11494543
Drug: Standard IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IFN therapy
Study: 9593129
Drug: Cefdinir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (300 mg twice a day for 5 days)
Study: 1838978
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (250 mg four times a day for 10 days)
Study: 31589545
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with Cochlear Implants (CCIs)
Study: 31589545
Drug: Postlingually deaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postlingually deaf adults with Cochlear Implants (CIs)
Study: 29850937
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg (pre-hemodialysis)
Study: 29850937
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg (post-hemodialysis)
Study: 29850937
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg (healthy subjects)
Study: 29850937
Drug: Ticagrelor (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (all treatments)
Study: 25230867
Drug: HVHF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVHF treatment (18 hours per day on days 1, 3, 5, 7)
Study: 25230867
Drug: PiCCO +
Normalized name: STATLOCK PICC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PiCCO + HVHF treatment
Study: 22412215
Drug: Survey administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey administered to both groups
Study: 17690799
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behavioral therapy (ICBT)
Study: 16218176
Drug: Once-daily saquinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
Study: 12117728
Drug: Dihydrotestosterone (DHT)
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (DHT) 70 mg transdermally daily
Study: 12117728
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human chorionic gonadotropin (rhCG) 250 microg twice weekly
Study: 388053
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (TF) treatment, 2 units of TF administered subcutaneously on days 1 and 15
Study: 8993769
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (TF) treatment
Study: 31479138
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (INR target 1.8)
Study: 31479138
Drug: Standard-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-intensity warfarin (INR target 2.5)
Study: 27484766
Drug: Aidi intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aidi intravenous injection plus NP regimen (2 cycles)
Study: 27484766
Drug: Aidi intratumor
Normalized name: ALCOHOL 80 mL in 100 mL INTRATUMOR LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aidi intratumor injection plus NP regimen (2 cycles)
Study: 25933151
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine HCl + 1/200,000 epinephrine (10 mL)
Study: 25933151
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine HCl + 1/200,000 epinephrine (10 mL)
Study: 25933151
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (10 mL)
Study: 19732673
Drug: Precomprehensive orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precomprehensive orthodontic treatment
Study: 19732673
Drug: Postinterceptive orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postinterceptive orthodontic treatment
Study: 19732673
Drug: Overall and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall and oral health QoL
Study: 9732919
Drug: Eradicating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradicating treatment (Group 1)
Study: 9732919
Drug: Eradicating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradicating treatment (Group 2 after initial follow-up)
Study: 8277068
Drug: Heparin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (15 IU/kg body weight per h) with aspirin
Study: 23895505
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1 g twice daily
Study: 23895505
Drug: EPA and
Normalized name: Norwegian Cod Liver Oil With EPA and DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA and Aspirin combination
Study: 23895505
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Aspirin
Study: 20880282
Drug: Feeding daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding daily to satiation (FD)
Study: 15479360
Drug: Intravenous lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lansoprazole 30 mg
Study: 15479360
Drug: Oral lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lansoprazole 30 mg
Study: 11340101
Drug: Oats diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oats diet (45 g/(4.2 MJ dietary energy. d), n = 22)
Study: 26080338
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (intravenous ertapenem 1 g/d for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Study: 26080338
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (standard open appendectomy)
Study: 22008822
Drug: PCV13 toddler
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 toddler dose
Study: 20107684
Drug: Beverage mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage mixed with 25 g of rapadura and 40 mg of ascorbic acid (per 200-mL serving)
Study: 20107684
Drug: Beverage sweetened
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage sweetened with 25 g of standard refined sugar and 40 mg of ascorbic acid (per 200-mL serving)
Study: 15639694
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/d
Study: 11005269
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy for 6 months
Study: 11005269
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy for 12 months
Study: 3086024
Drug: L‐rhamnose
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐rhamnose
Study: 3419838
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (US) at 0.1 W/cm2
Study: 27554689
Drug: Thigh-high 30-40
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh-high 30-40 mm Hg compression therapy for 7 days
Study: 24524874
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no physical therapy)
Study: 16213869
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (dosage not specified)
Study: 3389864
Drug: Oxandrolone, 2.5
Normalized name: Oxandrolone, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone, 2.5 mg per day (mean dose 0.072 mg/kg/day)
Study: 3389864
Drug: Oxandrolone, 2.5
Normalized name: Oxandrolone, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone, 2.5 mg per day (mean dose 0.073 mg/kg/day) after placebo
Study: 31199462
Drug: methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate (0.3 mg/kg, twice a day for 2 weeks)
Study: 23927594
Drug: Cynatine® FLX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cynatine® FLX (500 mg per day for 60 days)
Study: 23927594
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, identical dosage for 60 days)
Study: 17583186
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (1000 mg)